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Background: The European Association of Nuclear Medicine procedure guidelines for whole-body
fluorodeoxyglucose positron-emission tomography (FDG-PET) scanning prescribe a dose proportional to the
patient’s body mass. However, clinical practice shows degraded image quality in obese patients indicating that
using an FDG dose proportional to body mass does not overcome size-related degradation of the image quality.
The aim of this study was to optimize the administered FDG dose as a function of the patient’s body mass or a
different patient-dependent parameter, providing whole-body FDG-PET images of a more constant quality.
Methods: Using a linear relation between administered dose and body mass, FDG-PET imaging was performed on
two PET/computed tomography scanners (Biograph TruePoint and Biograph mCT, Siemens). Image quality was
assessed by the signal-to-noise ratio (SNR) in the liver in 102 patients with a body mass of 46 to 130 kg. Moreover,
the best correlating patient-dependent parameter was derived, and an optimized FDG dose regimen was
determined. This optimized dose regimen was validated on the Biograph TruePoint system in 42 new patients.
Furthermore, this relation was verified by a simulation study, in which patients with different body masses were
simulated with cylindrical phantoms.
Results: As expected, both PET systems showed a significant decrease in SNR with increasing patient’s body mass
when using a linear dosage. When image quality was fitted to the patient-dependent parameters, the fit with the
patient’s body mass had the highest R2. The optimized dose regimen was found to be Anew = c/t × m
2, where m is
the body mass, t is the acquisition time per bed position and c is a constant (depending on scanner type). Using
this relation, SNR no longer varied with the patient’s body mass. This quadratic relation between dose and body
mass was confirmed by the simulation study.
Conclusion: A quadratic relation between FDG dose and the patient’s body mass is recommended. Both
simulations and clinical observations confirm that image quality remains constant across patients when this
quadratic dose regimen is used.
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The European Association of Nuclear Medicine (EANM)
procedure guidelines for whole-body fluorodeoxyglucose
positron-emission tomography(/computed tomography)
(FDG-PET(/CT)) scans for tumour imaging [1] provide
a standardization for the administration of FDG and the* Correspondence: e.h.de.groot@umcg.nl
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in any medium, provided the original work is pacquisition and reconstruction of an FDG whole-body
PET scan. Together with quality control standards, these
guidelines ensure that the measured FDG tumour up-
take is, within certain limits, independent of the system
used or the centre where the study is performed. Fur-
thermore, it was discussed that the linear relationship
between the patient’s body mass and administered FDG
dose would result in a more uniform image quality be-
tween patients compared to a constant administered
dose. However, it is well known from clinical practice
that even after adherence to the guidelines, the images an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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obese patients, which can result in false-negative PET
scans. Thus, a different relationship between dose and
body mass or a different patient-dependent parameter, e.g.
body mass index (BMI) or lean mass, might be required to
obtain an even more constant image quality [2,3]. Research
on image quality has been performed at various institutes
[4,5], also with a special focus on obese patients [6,7].
Using the signal-to-noise ratio (SNR) in the liver as a
measure for image quality, the use of a higher FDG dose
per kilogram of body mass (typically 6 to 10 MBq/kg) or
longer PET acquisition times per bed position for patients
with high body mass were suggested [5,8]. However, the
optimal relationship has not yet been determined. For chil-
dren, an optimized dose regimen using an exponential rela-
tion between body mass and FDG dose was suggested [9].
Thus, the aim of this study was to optimize the admin-
istered FDG dose as a function of a patient-dependent
parameter, providing whole-body FDG-PET images of a
more constant quality.
Since the publication of [1], more PET cameras have
been equipped with a time of flight (TOF) option [10-12].
In addition, reconstructions using a position-dependent
point spread function (PSF) have also been introduced
[13]. It is possible that these new reconstruction options
change the optimal relation between the patient-dependent
parameter and the administered FDG dose. Therefore,
these different reconstruction methods were taken into
account in this study.
Methods
For all parts of the study, the patients were scanned ac-
cording to the standard clinical protocol valid at the mo-
ment of their scan at their hospital. Based on the outcome
of the first part of the study, the standard clinical protocol
at the site of the Biograph TruePoint was changed. So, in
this study all analyses were performed retrospectively on
anonymized clinical patient data. Therefore, approval by
the medical ethics committee was not required.
The statistical analysis was performed using SigmaPlot
for Windows, version 10.0 (Systat Software Inc., Chicago,
IL, USA).
First part of the study
First, a retrospective analysis was performed on the image
quality of whole-body FDG-PET scans for two groups of
patients in two hospitals. For both groups, local administra-
tion and scanning protocols were followed. One group,
consisting of 40 patients, underwent PET/CT on a Siemens
Biograph 40 TruePoint camera with TrueV (Knoxville, TN,
USA). The second group, consisting of 62 patients, under-
went PET/CT on a Siemens Biograph mCT camera with a
64-slice CT. An overview of patient characteristics and
acquisition parameters is given in Table 1. In all cases, PETimages were reconstructed using three-dimensional ordered
subset expectation maximization (OSEM3D), with CT-
based attenuation correction. For the Biograph mCT, also
the position-dependent PSF and TOF options were used.
The reconstruction parameters that were used are summa-
rized in Table 2. The patients for both the first and the sec-
ond part of the study were primarily selected consecutively
from the patients that were scanned in the hospitals. How-
ever, heavier patients (>90 kg) were specifically selected in
the end to obtain a better spread in the patient’s body mass.
On the Biograph mCT, all patients were scanned with
their arms above their head; on the Biograph TruePoint,
part of the patient group was scanned with their arms
along their body.
As a measure of image quality, the SNR in the liver was
used as it is the only organ in the human body that has a
relatively homogeneous uptake of FDG. Patient scans with
inhomogeneous uptake, particularly due to liver metasta-
sis or other irregularities in the liver, were excluded from
this study. The SNR is defined as the ratio of the mean





As nuclear positron emission is a Poisson-distributed
random process, PET is a statistical imaging technique
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where N is the number of disintegrations measured, A is
the activity (MBq) in the region of interest measured
and t is the scan time per bed position (min).
The SNR in the liver (SNRL) was calculated as follows.
The transverse CT slice in which the liver has the largest
cross section was determined. In the corresponding PET
slice and three adjacent slices, a region of interest (ROI)
was drawn in the liver, in which the mean pixel value and
standard deviation were measured. The ROI was identical
in all four slices and was drawn far enough from the edges
of the liver to avoid partial volume effects. The SNRL was
calculated for each ROI using Equation 1 and was then
averaged for the four ROIs. To investigate whether SNRL
decreases significantly with body mass, it was corrected
for the different scan times per bed position, by dividing it
by the square root of the acquisition time per bed position
(based on Equation 2). Then a linear regression of SNRL/
√t with body mass was performed. The slope of the re-
gression line was regarded to be significantly different
from zero if p < 0.05.
Table 1 Patient characteristics and acquisition parameters
Part of study
First part First part Second part
Camera Biograph TruePoint Biograph mCT Biograph TruePoint
Number of patients 40 62 42
Body mass (kg)
Mean ± SD 80.9 ± 21.1 82.6 ± 18.0 80.3 ± 23.7
Range 50 to 130 46 to 125 45 to 125
Length (m)
Mean ± SD 1.72 ± 0.10 1.76 ± 0.11 1.73 ± 0.10
Range 1.52 to 1.95 1.53 to 1.99 1.45 to 1.99
Time between administration and scan (min), (range) 60 (53 to 65) 60 (55 to 65) 63 (54 to 98)
PET acquisition mode 3D 3D 3D
Prescribed FDG dose (MBq)
Body mass < 90 kg 2.13·m 5·m 0.023·(m2.047)
Body mass > 90 kg 191.7 + 5·(m − 90) 5·m 0.023·(m2.047)
Acquisition time per bed position (min)
Body mass < 60 kg 4 1 4
Body mass = 60 to 90 kg 4 2 4
Body mass > 90 kg 4 3 4
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where A is the administered dose (MBq) and t is the
acquisition time per bed position (min).
The uptake of FDG is related to body mass, but alterna-
tive patient-dependent parameters may be more appropri-
ate [2]. Therefore, SNRnorm was displayed as a function of
various patient-dependent parameters and fitted with a
single polynomial function, given by Equation 4. The 95%
confidence intervals (95% CIs) were also calculated for
these fits:
SNRfit ¼ a⋅p−d; ð4Þ
where SNRfit ((MBq min)
−1/2) is the result of the fit, a
and d are fit parameters and p is a patient-dependent




Biograph mCT OSEM3D + PSF
Biograph mCT OSEM3D + PSF + TOFThe tested patient-dependent parameters were body
mass, BMI, lean body mass as defined by Hume [14] and
James [15], fat mass (defined by body mass minus the
lean body mass) and body mass per body length. These
parameters were chosen because they are related to body
shape and fat content. Based on the coefficient of deter-
mination (R2), the best patient-dependent parameter
was selected. The relative error between SNRnorm and
SNRfit was calculated for each data point using (SNRfit −
SNRnorm)/SNRfit × 100%. An F test was performed to
test if the standard deviation of the relative error distri-
bution of the different fits differed significantly from that
of the fit with the patient-dependent parameter with the
highest R2. The level of statistical significance was set to
0.05 (not corrected for multiple comparisons). Combin-
ation of Equations 3 and 4 shows that SNRL, and hence




⋅a⋅p−d ¼ constant: ð5Þ
The value of the constant in Equation 5 equals an ac-
ceptable SNRL (SNRacc), which is the value of the SNRLameras





Figure 1 Axial slice with ROI. An axial slice of one of the patient
scans showing the ROI used to derive the SNR in the liver (red contour).
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image quality is still acceptable. This SNRacc was chosen
by an experienced nuclear medicine physician. In this
study this was done for the Biograph TruePoint. From
Equation 5, it follows that the dose regimen described by
Equation 6 should result in a more constant image qual-









Second part of the study
After determination of the optimized dose regimen for
the Biograph TruePoint PET/CT device, it was imple-
mented as the new routine clinical protocol. From the
ensuing pool of clinical patient data, 42 scans were ex-
tracted and analyzed to investigate the effect of this new
clinical protocol on image quality. An overview of pa-
tient characteristics and acquisition parameters is given
in Table 1. The analysis of the SNRL was repeated for
these 42 patients, and it was checked using linear regres-
sion if the SNRL was independent of the patient’s body
mass for this group. The slope of the regression line was
regarded to be significantly different from zero if p < 0.05.
Simulation study
In order to support clinical findings and to get a more
detailed understanding of the relationship between the
administered FDG dose as a function of the patient’s body
mass and image quality, several 2D simulations were per-
formed. Patients with different body masses were simulated
with a cylindrical mathematical phantom having different
diameters of 15, 20, 25 and 30 cm. Assuming a body length
of 1.75 m, these diameters correspond to body masses of,
respectively, approximately 31, 55, 85 and 125 kg. For each
simulated phantom, an emission sinogram was generated
by forward projection of the image to sinogram space (144
angles, 4-mm bins, image matrix = 128 × 128). Effects of
attenuation were included assuming a uniform water equiv-
alent density in the mathematical phantom (attenuation co-
efficient μ = 0.095 cm−1). Poisson noise was then added to
the attenuated sinograms, and a total of 50 noisy sinogram
replicates were generated. Dead time and contribution of
random coincidences and scattered photons were not
included. Next, each of the 50 sinograms was recon-
structed using attenuation-weighted ordered subset ex-
pectation maximization (AW-OSEM) using 4 iterations
and 16 subsets. Simulations were performed using three
FDG dose-body mass relations: (1) a fixed dose independ-
ent of the patient’s body mass, resulting in decreasing
activity concentration with increasing patient’s body mass
in the simulated image; (2) a linear relation between thepatient’s body mass and the administered dose, resulting in
a constant activity concentration in the patient (or math-
ematical phantom), as currently recommended by the
EANM guidelines for quantitative FDG PET/CT imaging
in oncology [1]; and (3) a quadratic relation between the
patient’s body mass and the administered dose, resulting in
an increase of activity concentration in the patient (phan-
tom) with increasing body mass. A constant scan duration
was assumed for all simulations. To simplify the compa-
rison between the three relations, the simulations are
designed such that the 20-cm-diameter phantom data pro-
vide equal results for the three different dose regimes. The
SNR in the reconstructed images was assessed within a
circular ROI with a diameter which was 4 cm less than the
diameter of the simulated cylinder (i.e. the 2-cm outer edge
of the phantom was not included). The values of the SNR
seen in individual images were then averaged over all 50
replicates to obtain a more precise estimate of image SNR.
Results
First part of the study
Figure 1 shows an example of a ROI used to determine the
SNRL. Figure 2A shows the relation between the measured
SNRL and the patient’s body mass for the Biograph
TruePoint after OSEM3D reconstruction. Figure 2B shows
the relation between the SNRL corrected for the acquisi-
tion time per bed position and the patient’s body mass
for the same camera. Figure 2C,E,G shows the relation
between the SNRL and the patient’s body mass for the Bio-
graph mCT. Figure 2D,F,H shows the relation between the
SNRL corrected for the acquisition time per bed position
and the patient’s body mass for the Biograph mCT for all
three reconstructions. Figure 2C,E,G shows that the ap-
plied relation between body mass and acquisition time per
Figure 2 SNRL and SNRL/(t
1/2) versus body mass. Signal-to-noise ratio in the liver (SNRL) versus body mass (left) and SNRL normalized to an
acquisition time per bed position of 1 min versus body mass (right) for the Biograph TruePoint (TP), OSEM3D reconstruction (A, B) and the
Biograph mCT for three different reconstructions: (C, D) OSEM3D, (E, F) OSEM3D + PSF, and (G, H) OSEM3D + PSF + TOF. The lines in the graphs
are the result of linear regression of the data.
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the SNRL decline normally seen (cf. Figure 2A) in heavy
patients. After normalization for the acquisition time per
bed position (Figure 2B,D,F,H), a significant decrease in
the SNRL with body mass was observed for both cameras
(p < 0.001). This is illustrated in Figure 3A,B, showing ascan of a patient with a body mass of 70 kg and that of a
patient with a body mass of 95 kg, respectively.
The results of the fits of SNRnorm, against various patient-
dependent parameters, as well as the p values of the F test
compared to body mass are given in Table 3. Table 3 shows
that based on the values of R2, the best fits are those where
Figure 3 Patient scans in the old and new dose regimens. Coronal and transverse slices of a whole-body FDG-PET scan for (A) a patient of
70 kg (dose = 149 MBq) and (B) a patient of 95 kg (dose = 217 MBq), using the old dose regimen, and for (C) a patient of 70 kg (dose = 138
MBq) and (D) a patient of 95 kg (dose = 257 MBq), using a quadratic relation between body mass and FDG dose. Using the old relation between
body mass and dose, the dose would have been (C) 149 and (D) 217 MBq, respectively. All four scans were performed on the Biograph
TruePoint. The location of the transverse slice is indicated on the coronal view.
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dependent parameters. We chose to use the body mass
further on in the analysis because this will be the easiest to
implement in the clinic and its fit with SNRnorm has the
highest R2. In Figure 4, the fits and their 95% CI of the
SNRnorm with the patient’s body mass are shown for both
PET/CT cameras.
Second part of the study
For the second part of the study, the SNRacc was deter-
mined to be 9.58, corresponding to the image quality of
a patient with a body mass of 75 kg in the linear dose
regimen. According to Equation 6 and using the fit data
from Table 3, this gives the optimized dose regimen (A
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This new dose regimen for the Biograph TruePoint
(Equation 7) was validated for a group of 42 new pa-
tients. The results are shown in Figure 5. It is seen from
this figure that the SNRL no longer decreases with body
mass (p = 0.98). This is also illustrated by the patient
scans in Figure 3C,D. The body masses of these two pa-
tients are equal to the body masses of the patients in
Figure 3A,B. However, the image quality for the heavier
patient is now similar to that of the lighter patient.Simulation study
Figure 6 shows representative axial slices of the simu-
lated mathematical phantom with various diameters. The
results of the simulations were well in line with clinical
observations. The use of a fixed amount of FDG dose
resulted in a large change in image quality or decreasing
SNR with increasing phantom diameter, i.e. increasing
body mass (Figure 7). Using a linear relation between body
mass and FDG dose, this reduction was still approximately
a factor of 2 between phantoms representing patients hav-
ing a body mass of 55 and 125 kg, respectively (Figure 7).
When simulated administered FDG dose was proportional
to the square of the patient’s body mass, image noise
remained fairly constant (within 30% difference) across
the range of simulated patient’s body masses.
Discussion
The current EANM guidelines [1] advise a linear relation
between FDG dose and body mass. The data in Figure 2C,
E,G were obtained using a linear relation between the pa-
tient’s body mass and the FDG dose, but the scan time per
bed position was varied for different classes of body mass.
However, this adaption in the scan time can be corrected
for, based on Equation 2. The results of this correction are
shown in Figure 2D,F,H. From these figures, it is clearly
seen that the EANM guidelines result in a decreasing SNRL
with increasing body mass for the Biograph mCT for all
reconstructions used in this study. The regression lines in
Figure 2A,B were obtained using the data of all patients
Table 3 Fit of SNRnorm with various patient-dependent parameters
Patient-dependent
parameter
Biograph TruePoint Biograph mCT
OSEM3D OSEM3D + PSF + TOF OSEM3D + PSF OSEM3D
a d R2 p value of F test a d R2 p value of F test a d R2 p value of F test a d R2 p value of F test
Body mass (kg) 31.43 1.02 0.93 - 63.57 1.22 0.77 - 24.47 0.99 0.79 - 30.19 1.08 0.84 -
BMI (kg/m2) 11.16 1.04 0.78 <0.001* 19.20 1.28 0.52 0.003* 11.28 1.10 0.56 0.006* 13.11 1.20 0.59 <0.001*
Lean body mass (Hume, kg) 63.07 1.30 0.72 <0.001* 90.26 1.42 0.68 0.200 37.69 1.19 0.69 0.145 47.30 1.30 0.72 0.058
Fat mass (Hume, kg) 1.60 0.47 0.80 0.001* 2.01 0.60 0.64 0.065 1.61 0.51 0.67 0.081 1.56 0.56 0.71 0.035*
Lean body mass (James, kg) 20.41 1.01 0.49 <0.001* 46.46 1.24 0.65 0.119 21.44 1.03 0.65 0.086 25.68 1.13 0.69 0.030*
Fat mass (James, kg) 1.39 0.44 0.75 <0.001* 1.66 0.57 0.56 0.009* 1.37 0.49 0.59 0.010* 1.31 0.54 0.63 0.002*
Mass per length (kg/m) 23.49 1.09 0.91 0.325 49.14 1.34 0.71 0.400 24.16 1.13 0.74 0.513 29.97 1.24 0.78 0.363





















Figure 4 SNRnorm versus body mass. Signal-to-noise ratio normalized for the administered FDG dose and scan time per bed position (SNRnorm)
versus body mass. Besides the best fits through the data, also their 95% confidence intervals are shown, and the best fit with the value of the
parameter d fixed to 1 for (A) the Biograph TruePoint (TP) and for the Biograph mCT for three different reconstructions: (B) OSEM3D, (C) OSEM3D + PSF
and (D) OSEM3D + PSF + TOF. The fit with the parameter d fixed to 1 corresponds to the situation where SNRL can be kept constant by a quadratic
relation between dose and body mass.
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study. However, patients with a body mass above 90 kg
received a higher FDG dose per kilogram of body mass for
every kilogram over 90 kg (see Table 1). This higher dose
might compensate for the decline of SNRL for heavier
patients. However, if two separate regression analyses are
performed for these two classes of body mass, it turns out
that for both groups the SNRL decreases significantly with
body mass (p < 0.001 and p = 0.03, respectively). So evenFigure 5 Comparison between the old and new dose regimens.
SNRL versus body mass for the old and new dose regimens for the
Biograph TruePoint.though patients with a body mass above 90 kg were admin-
istered a higher FDG dose per kilogram of body mass, the
SNRL also decreases with body mass for this group on the
Biograph TruePoint. The first part of the study indicated
that for both cameras a quadratic relation between FDG
dose and body mass should result in a more constant SNRL
and that this is valid for all the reconstruction methods
used. Validation of this new dose regimen showed that a
quadratic dose regimen actually results in a more constant
SNRL. These results are consistent with clinical observa-
tions, indicating that the use of the SNR as measured in
the liver is a good parameter to investigate the relation be-
tween body parameters and image quality. The reason that
the liver was chosen is that this is the only organ that has a
relative homogeneous uptake of FDG. However, SNRL alsoFigure 6 Axial slices of the simulated mathematical phantom.
Representative axial slices of the simulated mathematical phantom with
various diameters. Images were taken from the simulation applying a
linear relationship between weight and administered activity. The
region of interest to derive SNR is indicated by the red contour.
Figure 7 Simulation results. SNR versus the body mass
represented by the phantom for constant, linear and quadratic dose
regimes using AW-OSEM reconstruction. The error bars represent
two standard deviations.
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eity of liver uptake was the only exclusion criterion for this
study, it is expected that our results can be extrapolated to
all FDG whole-body scans.
The fit of SNRnorm to different patient-dependent pa-
rameters shows that the fit with body mass has the
highest R2, followed by mass per length (the difference of
R2 is not significant for both cameras). Fits of SNRnorm
with lean body mass, fat mass and BMI turned out to have
lower values of R2, sometimes significantly so. Based on
these findings and the fact that body mass is the easiest
patient-dependent parameter to use, the choice for body
mass was made. It may be surprising that fits of SNRnorm
with lean body mass, fat mass and BMI have lower values
of R2 than the fit with body mass as one would assume
that body shape should influence image quality. Appar-
ently, in our population, this is only a minor effect since
body mass already explains between 77% and 93% of the
variability in SNRnorm. The remaining error in the fit of
SNRnorm with body mass showed no trend with the pa-
tient’s body mass (data not shown), indicating that includ-
ing additional powers of body mass will not improve the
value of R2 of the fit of SNRnorm with body mass. Of
course, the effect of other body parameters may be hidden
in the remaining unexplained variance. However, a multi-
variate fit would overcomplicate the application of im-
proved dose regimes and probably reduce inter-subject
variability only marginally. Since the fit of SNRnorm with
body mass has the highest R2 and is easily obtained and a
very practical parameter to use, only the relation between
SNRnorm and body mass was considered further.
Analyzing the data, we determined that a quadratic rela-
tion between the patient’s body mass and administered
dose should result in a more constant SNRL, i.e. an imagequality that is less dependent of the patient’s body mass.
From Table 3, it is seen that for both TOF and non-TOF
systems, the fitting parameter d is approximately, but not
exactly equal to, 1. The obtained relationship between the
patient’s body mass and the administered FDG dose
(Equation 6) is therefore not exactly quadratic. The stand-
ard deviation of the relative error distribution of the fits
varies, depending on the reconstruction used, from 7.3%
to 15.3%. To determine the influence of this deviation of
the parameter d of the value of 1, the best fit between
SNRnorm and body mass for d = 1 is displayed in Figure 4
too. It is seen from Figure 4 that for three out of the four
cases the fit with d = 1, which would result in an exact
quadratic relation between the patient’s body mass and
the FDG dose, lies within the 95% CI of the best fit. Only
for the Biograph mCT, OSEM3D + PSF + TOF recon-
struction, the fit for d = 1 lies partly outside the 95% CI of
the best fit. However, this deviation is small. Therefore, it
was reasonable to state that the optimal relation between
the patient’s body mass and the FDG dose is quadratic.
Equation 6 was based on the assumption that the SNR
scales with the square root of the measured counts
(Equation 2), i.e. that N is proportional to A, where A is
the amount of activity at the time of administration. This
assumption was checked for OSEM3D, OSEM3D + PSF
and OSEM3D + PSF + TOF reconstructions by performing
scans of different acquisition times of a cylindrical phan-
tom uniformly filled with 68Ge (data not shown). The activ-
ity in the phantom was low enough to avoid dead time
effects. The fit of the SNR with the scan time showed that
SNR is proportional to tn, where the parameter n varied
from 0.44 to 0.47, depending on the reconstruction used.
However, it turns out that if these exact values are used in
the analysis, the values of d do not change significantly.
For both cameras, the waiting period between the adminis-
tration of FDG and the start of the PET acquisition was
standardized (1 h) and the total scan times were relatively
short compared to the half-life of FDG, which makes it rea-
sonable to assume that N is proportional to A. On the
Biograph mCT, different scan times per bed position were
used for different classes of body mass. This introduces a
difference in the time between FDG administration and
the start of the acquisition of the PET slice containing the
liver for patients with different body masses. However, this
difference will be only a couple of minutes, which is short
compared to the half-life of FDG. Therefore, the use of
Equation 2 was justified.
As we have shown, the product of the dose and the
time per bed position determines the SNRL (Equation 6).
Therefore, the acquisition time per bed position can, in
principle, be varied without influencing the image quality,
as long as the administered FDG dose is changed accord-
ingly. However, this study assumes that other effects which
influence image quality such as dead time correction as
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fore, one should be careful when increasing the FDG dose
in favour of a shorter acquisition time per bed position be-
cause dead time effects can influence the image quality
negatively. In this study the noise equivalent count rate
(NECR) remained in the linear range with respect to the
administered FDG dose. However, if higher doses are
applied, which is, e.g. the case in the USA [16], this is no
longer the case, and dead time effects become more im-
portant. For very heavy patients and without adapting the
scan time, the quadratic dose regimen results in very high
levels of administered dose and system dead time should
then be monitored. In addition to the decrease of dead
time effects, the use of longer acquisition time per bed pos-
ition for obese patients also has the benefit of reducing the
radiation burden for both the patient and the technician.
A quadratic dose regimen may be considered less prac-
tical than a linear relation, although this should not be
a problem when using automated dispensing units or a
lookup table. Alternatively, one could also linearize the
quadratic relation in parts or use a linear dose regimen
while adapting the acquisition time per bed position with
the patient’s body mass to mimic the quadratic relation
according to Equation 6. The latter approach was used on
the Biograph mCT, resulting in the data of Figure 2C,E,G.
The value of SNRacc was in this study only determined
for the OSEM3D reconstruction of the BiographTruePoint
camera. Because noise has a different structure in PSF and
PSF + TOF reconstructions compared to OSEM3D recon-
structions, the values of the SNR of different reconstruc-
tion methods are not directly comparable, and the value of
SNRacc has to be determined separately for different recon-
struction methods. The analysis in this paper was per-
formed on two Siemens cameras. Apparently, for the
systems tested, the quadratic relation is valid for OSEM3D
with or without PSF or PSF + TOF reconstructions. This
does not automatically mean that the obtained relationship
is also valid for cameras of different manufacturers or for
different reconstruction methods. Ideally, for these cam-
eras and reconstruction methods, one should repeat the
analysis of the SNRL. Nevertheless, we would not be sur-
prised if our results hold for other systems too.
Under this assumption, the new, quadratic dose Aq
(MBq) for a patient with body mass m (kg) depends on
the old, linear dose Alin (MBq) for this patient through




where mT is the maximum body mass up to which the
image quality is considered acceptable in the linear dose
regimen.The results of the simulations were in line with clinical
observations and confirm that at FDG activities as rec-
ommended by EANM (approximately in the range of
180 of 260 MBq for a patient with a body mass of 75 kg)
[1], image quality, expressed as SNR, remained fairly con-
stant across patients with different body masses when the
amount of FDG dose administered was proportional with
the square of the patient’s body mass. Simulations suggest
that this relationship can be primarily explained by the
increased attenuation with increasing tissue mass as dead
time and contribution of random coincidences and scat-
tered photons were not included. Although the latter omis-
sions can be considered as a limitation of the simulations, it
should be noted that typical FDG activities administered in
Europe [1] are much lower than those applied in, for ex-
ample, the USA [16,17]. Consequently, PET/CT studies in
Europe are usually operated in the linear part of the NECR
curve, where the contributions of dead time and random
coincidences have a much smaller effect on NECR than at
higher FDG activities where the NECR curve becomes flat
[4]. SNR in patients can be influenced by physiology as well.
Changes in plasma clearance, obesity and/or plasma glu-
cose levels can have an effect on the biodistribution of FDG
and thus SNR. However, this study shows that these effects
are either rare or not as important as the effect of attenu-
ation. For example, by simply simulating effects of atten-
uation on image quality (SNR), we were able to closely
replicate the clinical findings, i.e. a linear relation between
the patient’s body mass and administered FDG dose was
not sufficient to achieve uniform image quality across
patients. By proportionally scaling the FDG dose with the
square of the body mass, a more uniform image noise level
as a function of (simulated) patient body mass can be
achieved. For patients heavier than approximately 120 kg,
the simulations indicate that an FDG dose proportional to
a higher power of the body mass is needed to obtain the
same SNR as for lighter patients. However, patients in this
range of body mass are rare in our settings and thus rare in
our analysis. Therefore, we cannot compare in full these
specific simulation results to clinical data.
The lowest patient’s body mass in this study was 45 kg.
It remains to be shown whether our results can be extrap-
olated to lower body masses. In addition, it also important
to note that the results obtained in this paper are only
valid for adults. For children, one should therefore use
current international guidelines such as those from the
EANM [18] or optimized dose regimes such as [9].
Conclusion
Using a dose regimen based on [1], in which the relation
between the administered FDG dose and the patient’s
body mass is linear, a decreasing image quality for obese
patients was observed. Of the tested patient-dependent
parameters, fits of body mass and mass per length with
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chosen because it is the easiest parameter to implement
in the clinic. A quadratic relation between FDG dose and
the patient’s body mass is recommended as both simula-
tions and clinical observations confirm that image quality
remains constant across patients when this dose regimen
is used.
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regimen. A derivation is given on how to extract the recommended
quadratic relation between dose and body mass, directly from the linear
dose strategy that is currently applied in clinical practice. Eventually, it
results in determining the maximum body mass up to which the image
quality is considered acceptable in the linear dose regimen.
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